VTGN vs. PTI, MACK, PGEN, ORGO, VNDA, NLTX, VRCA, XERS, STTK, and NKTX
Should you be buying Vistagen Therapeutics stock or one of its competitors? The main competitors of Vistagen Therapeutics include Proteostasis Therapeutics (PTI), Merrimack Pharmaceuticals (MACK), Precigen (PGEN), Organogenesis (ORGO), Vanda Pharmaceuticals (VNDA), Neoleukin Therapeutics (NLTX), Verrica Pharmaceuticals (VRCA), Xeris Biopharma (XERS), Shattuck Labs (STTK), and Nkarta (NKTX). These companies are all part of the "medical" sector.
Proteostasis Therapeutics (NASDAQ:PTI) and Vistagen Therapeutics (NASDAQ:VTGN) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, media sentiment, risk, earnings and community ranking.
Proteostasis Therapeutics has a net margin of 0.00% compared to Proteostasis Therapeutics' net margin of -3,073.51%. Proteostasis Therapeutics' return on equity of -72.10% beat Vistagen Therapeutics' return on equity.
In the previous week, Vistagen Therapeutics had 3 more articles in the media than Proteostasis Therapeutics. MarketBeat recorded 3 mentions for Vistagen Therapeutics and 0 mentions for Proteostasis Therapeutics. Proteostasis Therapeutics' average media sentiment score of 0.51 beat Vistagen Therapeutics' score of 0.00 indicating that Vistagen Therapeutics is being referred to more favorably in the news media.
Proteostasis Therapeutics received 36 more outperform votes than Vistagen Therapeutics when rated by MarketBeat users. However, 72.24% of users gave Vistagen Therapeutics an outperform vote while only 59.03% of users gave Proteostasis Therapeutics an outperform vote.
16.6% of Proteostasis Therapeutics shares are held by institutional investors. Comparatively, 78.4% of Vistagen Therapeutics shares are held by institutional investors. 4.8% of Proteostasis Therapeutics shares are held by insiders. Comparatively, 1.0% of Vistagen Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Proteostasis Therapeutics has a beta of 1.16, suggesting that its share price is 16% more volatile than the S&P 500. Comparatively, Vistagen Therapeutics has a beta of 0.69, suggesting that its share price is 31% less volatile than the S&P 500.
Vistagen Therapeutics has a consensus target price of $19.00, indicating a potential upside of 423.42%. Given Proteostasis Therapeutics' higher possible upside, analysts plainly believe Vistagen Therapeutics is more favorable than Proteostasis Therapeutics.
Proteostasis Therapeutics has higher revenue and earnings than Vistagen Therapeutics.
Summary
Vistagen Therapeutics beats Proteostasis Therapeutics on 8 of the 15 factors compared between the two stocks.
Get Vistagen Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for VTGN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VTGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Vistagen Therapeutics Competitors List
Related Companies and Tools
